{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:23:14Z","timestamp":1778505794206,"version":"3.51.4"},"reference-count":19,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by severe pruritus and eczematous skin lesions. Subcutaneous immunotherapy (SCIT) refers to repeated contact with gradually increasing doses of allergen extracts, which\n improve patient tolerance to such allergens and controls, or reduces allergic symptoms. This study aimed to explore the long-term efficacy and safety of SCIT for patients with AD sensitized to house-dust mite (HDM).  <jats:bold>Methods:<\/jats:bold> We conducted a retrospective analysis of 378\n patients with HDM-sensitized AD. Among these patients, 164 received SCIT plus pharmacotherapy for 3 years (SCIT group) and the other 214 patients received only pharmacotherapy (non-SCIT group). The scoring atopic dermatitis (SCORAD) and pruritus visual analog scale (VAS) scores, laboratory\n test results, and adverse effects were recorded.  <jats:bold>Results:<\/jats:bold> The SCORAD and pruritus VAS scores significantly decreased in the SCIT group. Also, the SCIT group showed higher reduction ratios of SCORAD and pruritus VAS scores than those observed in the non-SCIT group at 3 years\n after treatment initiation. The risk of development of new sensitization was higher in the non-SCIT group than in the SCIT group (relative risk 1.92 [95% confidence interval {CI}, 1.30\u20102.85]; p &lt; 0.05). The eosinophil count of the participants significantly differed in the complete\n response (CR) group (p &lt; 0.05) but not in the non\u2010CR group (p = 0.098). However, the serum total immunoglobulin E value was not significantly reduced (p = 0.204). Of 8421 injections given to the patients, 231 injections (2.74%) showed adverse effects during the treatment period.\n  <jats:bold>Conclusion:<\/jats:bold> Three years of SCIT can significantly reduce the severity and pruritus of moderate-to-severe AD with HDM sensitization. Patients who are multisensitized can also benefit from HDM SCIT. Patients can achieve long-term effects, such as prevention of neoallergen sensitization\n and inhibition of the allergy march.<\/jats:p>","DOI":"10.2500\/aap.2021.42.200126","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T04:52:24Z","timestamp":1615265544000},"page":"e47-e54","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis"],"prefix":"10.2500","volume":"42","author":[{"given":"Jie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/all.13420","article-title":"EAACI guidelines on allergen immunotherapy: executive statement","volume":"73","author":"Muraro","year":"2018","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/jdv.12813","article-title":"Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite","volume":"29","author":"Zhong","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1900598","DOI":"10.1183\/13993003.00598-2019","article-title":"The Global Initiative for Asthma (GINA): 25 years later","volume":"54","author":"Boulet","year":"2019","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/ajra.2016.30.4367","article-title":"Mechanism of action of allergen immunotherapy","volume":"30","author":"\u015eahin","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"B9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaci.2013.09.043","article-title":"Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation","volume":"133","author":"Suarez-Fueyo","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jama.2016.21040","article-title":"Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial","volume":"317","author":"Scadding","year":"2017","journal-title":"JAMA"},{"key":"B11","first-page":"81","article-title":"Chinese guideline for diagnosis and treatment of atopic dermatitis (2020)","year":"2020","journal-title":"Chinese J Dermatol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","article-title":"Atopic dermatitis and the atopic march","volume":"112","author":"Spergel","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drudis.2015.07.010","article-title":"Allergy immunotherapy: the future of allergy treatment","volume":"21","author":"Larsen","year":"2016","journal-title":"Drug Discov Today"},{"key":"B14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/pai.12661","article-title":"Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis","volume":"28","author":"Kristiansen","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/all.13104","article-title":"Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review","volume":"72","author":"Di Bona","year":"2017","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1046\/j.1365-2222.2001.01161.x","article-title":"Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study","volume":"31","author":"Pajno","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"B17","first-page":"85","article-title":"Prevention of new sensitizations by specific immunotherapy in children with rhinitis and\/or asthma monosensitized to house dust mite","volume":"17","author":"Inal","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/pai.13261","article-title":"Systemic and large local reactions during subcutaneous grass pollen immunotherapy in children","volume":"31","author":"Gur Cetinkaya","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.anai.2016.01.015","article-title":"Local and systemic reactions to subcutaneous allergen immunotherapy: ten years' experience in a pediatric clinic","volume":"116","author":"Nacaroglu","year":"2016","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/00000002\/art00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T04:58:09Z","timestamp":1615265889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.200126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["1088-5412(20210301)42:2L.47;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.200126","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}